 ATLANTA, Jan. 19, 2021 GLOBE NEWSWIRE -- Alimera Sciences, Inc. Nasdaq: ALIM Alimera, a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of 13.5 million and annual 2020 consolidated net revenue in excess of 50.5 million. Alimera anticipates that cash on December 31, 2020 will be 11.2 million compared to 11.3 million on September 30, 2020. 